Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Public ClinicalTrials.gov record NCT02805660. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT02805660
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab - 1500 mg Drug
- Mocetinostat - 50 mg Drug
- Mocetinostat - 70 mg Drug
- Mocetinostat - 90 mg Drug
- Mocetinostat - Recommended Phase 2 Dose (70 mg) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2016
- Primary completion
- Dec 13, 2019
- Completion
- Dec 19, 2019
- Last update posted
- Apr 5, 2021
2016 – 2019
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center, PC | Mobile | Alabama | 36608 | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90095 | — |
| Woodlands Medical Specialists - Pensacola | Pensacola | Florida | 32503 | — |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago | Illinois | 60611 | — |
| NorthShore University Health System | Evanston | Illinois | 60201 | — |
| Unniversity of Minnesota Masonic Cancer Center | Minneapolis | Minnesota | 55414 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research Centers | Dallas | Texas | 75230 | — |
| Texas Oncology - Denton South | Denton | Texas | 76210 | — |
| Texas Oncology-Plano West | Plano | Texas | 75093 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Shenandoah Oncology - Winchester | Winchester | Virginia | 22601 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02805660, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2021 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02805660 live on ClinicalTrials.gov.